References
1. Kishorbhai VT, Malaviya, M. . Overview of an ovarian cancer and its
treatment aspects. International Journal of Pharmaceutical and
Biological Science Archive. 2021;9(2):24-30.
2. Hamburg MA, Collins FS. The Path to Personalized Medicine. New
England Journal of Medicine. 2010;363(4):301-4.
3. Vogenberg FR, Isaacson Barash C, Pursel M. Personalized medicine:
part 1: evolution and development into theranostics. P & T : a peer-
reviewed journal for formulary management. 2010;35(10):560-76.
4. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: the promise of
personalized medicine. AAPS PharmSci. 2000;2(1):E4-E.
5. Mathur S, Sutton J. Personalized medicine could transform healthcare
(Review). Biomed Rep. 2017;7(1):3-5.
6. Javaid M, Haleem A. Industry 4.0 applications in medical field: A
brief review. Current Medicine Research and Practice. 2019;9(3):102- 9.
7. Ayers A. Personalized Medicine – Future Impact, Pharma Industry
Perspective. J Biomol Tech. 2010;21(3 Suppl):S5-S.
8.Molyneux D, Nantulya V. Public-private partnerships in blindness
prevention: Reaching beyond the eye. Eye (London, England).
2005;19:1050-6.
9.Bhatt P, Narvekar P, Lalani R, Chougule MB, Pathak Y, Sutariya V. An
in vitro Assessment of Thermo-Reversible Gel Formulation Containing
Sunitinib Nanoparticles for Neovascular Age-Related Macular
Degeneration. AAPS PharmSciTech. 2019;20(7):281.
10. Uddin M, Wang Y, Woodbury-Smith M. Artificial intelligence for
precision medicine in neurodevelopmental disorders. npj Digital
Medicine. 2019;2(1):112.
11. Jigar Vyas HP, Himan Patel. . Comparative Study of Etoricoxib Loaded
Solid Dispersion and Beta-cyclodextrin Complexes for improvement of
Dissolution Profile, Research Journal of Pharmaceutical Dosage Forms and
Technology. 2020;12(2):63-7.
12. Mathur S, Sutton J. Personalized medicine could transform
healthcare. Biomed Rep. 2017;7(1):3-5.
13.Personalized Medicine Coalition.https://personalizedmedicinecoalition.org/Retrieved Dec 4, 2021.
14. Dudley J, Karczewski K (2014). Exploring Personal Genomics .
Oxford: Oxford University Press.
15. Pirmohamed, M. “Pharmacogenetics and pharmacogenomics.”British journal of clinical pharmacology vol. 52,4 (2001): 345-7.
doi:10.1046/j.0306-5251.2001.01498.x
16. Xie J, Lee S, Chen X (August 2010). Donev R (ed.).
”Nanoparticle-based
theranostic agents”. Advanced Drug Delivery Reviews .
Personalized Medicine. Academic Press. 62 (11): 1064–79.
17. Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N
(March 2017).
”Theranostic
Biomarkers for Schizophrenia”. International Journal of Molecular
Sciences . 18 (4): 733.
18. Yahata N, Kasai K, Kawato M (April 2017).
”Computational neuroscience
approach to biomarkers and treatments for mental disorders”.Psychiatry and Clinical Neurosciences . 71 (4): 215–237
19. ”BIOMARKERTOOLKIT:
Companion Diagnostics”https://web.archive.org/web/20140801145112/http://www.amgen.com/pdfs/misc/vpk_biomarker_diagnostics.pdf
. Amgen. Archived fromthe
original . Retrieved Dec 4, 2021.
20. Pandey S, Giovenzana GB, Szikra D, Baranyai Z (2021). ”Chapter 11.
Positron Emission Tomography (PET) Driven Theranostics”. Metal
Ions in Bio-Imaging Techniques . Springer. pp. 315–346.
21. Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ,
Baumann M, et al. (March 2020).
”Radiotheranostics:
a roadmap for future development”. The Lancet. Oncology .21 (3): e146–e156
22. Carney W (2006).
”HER2/neu
Status is an Important Biomarker in Guiding Personalized HER2/neu
Therapy” (PDF). Connection. 9 : 25–27.
23. Telli ML, Hunt SA, Carlson RW, Guardino AE (August
2007). ”Trastuzumab-related cardiotoxicity: calling into question the
concept of reversibility”. Journal of Clinical Oncology. 25(23): 3525–33.
24. Saglio G, Morotti A, Mattioli G, Messa E, Giugliano E, Volpe G, et
al. (December 2004). ”Rational approaches to the design of therapeutics
targeting molecular markers: the case of chronic myelogenous leukemia”.
Annals of the New York Academy of Sciences. 1028 (1): 423–31.
25. Pleasance E, Titmuss E, Williamson L, et al. (2020).
”Pan-cancer analysis
of advanced patient tumours reveals interactions between therapy and
genomic landscapes”. Nature Cancer . 1 (4): 452–468.
26. Van Dongen GA, Poot AJ, Vugts DJ. PET imaging with
radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and
TKI-PET. Tumour biology : the journal of the International Society for
Oncodevelopmental Biology and Medicine. 2012;33(3):607-15.
27. Malaviya M, Shiroya M. Systemic gene delivery using lipid
envelope systems and its potential in overcoming challenges.
International Journal of Pharmaceutics and Drug Analysis.
2021;9(1):46-55.
28. Vanpariya F, Shiroya M, Malaviya M. Emulgel: A Review.
International Journal of Science and Research (IJSR). 2021;10:847.
29 Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR
antibody Fab’ fragment conjugated immunoliposomes loaded with
cyclodextrin-paclitaxel complex for improved in vitro efficacy on
ovarian cancer cells. Cancer research. 2016;76(14 Supplement):2065.
30. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek
P, et al. A CFTR Potentiator in Patients with Cystic Fibrosis and the
G551D Mutation. New England Journal of Medicine. 2011;365(18):1663-72.
31. Narvekar P, Bhatt P, Fnu G, Sutariya V. Axitinib-Loaded
Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Age-Related Macular
Degeneration: Formulation Development and In Vitro Characterization.
ASSAY and Drug Development Technologies. 2019;17(4):167-77.
32. Rose N. Personalized Medicine: Promises, Problems and Perils
of a New Paradigm for Healthcare. Procedia - Social and Behavioral
Sciences. 2013;77:341-52.
33. Vicente AM, Ballensiefen W, Jönsson J-I. How personalised
medicine will transform healthcare by 2030: the ICPerMed vision. Journal
of Translational Medicine. 2020;18(1):180.